Is there any role for adjuvant atezolizumab or adjuvant osimertinib in patients who received neoadjuvant chemotherapy for resectable NSCLC?  

Most of the neoadjuvant studies using either immunotherapy or targeted therapy before surgery have continued the therapy after surgery in responders. For IO, this has generally been 1 year. For targeted therapy, it may be as long as 3 years.